Join us on December 14 for our Patient-Focused Sessions on Multiple Myeloma, taking place in Charlotte, NC! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Tom Castles
Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.
Kristie L. Kahl
The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.
Jessica Skarzynski
In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Amy Paturel
In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.
Jessica Skarzynski
Here are the top 5 CURE stories for July 2019.
Kristie L. Kahl
With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
Jessica Skarzynski
The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
Katie Kosko
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

 
Kristie L. Kahl
The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.
Katie Kosko
Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×